Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kay, A. G. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kay, A. G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1978 All rights reserved

Monitoring Adverse Reactions to Antirheumatic Drugs

A. G. L. Kay


  Abstract

Drug monitoring systems have been developed in response to public concern over drug-related adverse events: no completely satisfactory method has yet been developed.

Drug associated morbidity and mortality is a major problem in the treatment of rheumatic diseases.

The damage to patients from recognized drug hazards can be reduced by close monitoring and sequential recording of results of investigations.

Previously unrecognized drug-associated adverse events can best be identified by prospective surveillance of new drugs. Methodological problems are considerable but not insurmountable. Rheumatologists need to apply a variety of strategies to drug monitoring, some of them involving international cooperation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.